Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or GEJ Adenocarcinoma
NCT07353684Phase 2Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- May 2025
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Beijing Friendship Hospital. Started May 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07353684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353684.